Legend Biotech Corporation Sponsored ADR (LEGN) reported $186.52 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 134.7%. EPS of -$0.15 for the same period compares to -$0.40 a year ago.

The reported revenue represents a surprise of +3.32% over the Zacks Consensus Estimate of $180.53 million. With the consensus EPS estimate being -$0.39, the EPS surprise was +61.54%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Legend Biotech performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Collaboration: $168.02 million compared to the $169.20 million average estimate based on seven analysts.
• Revenues- License: $18.28 million compared to the $12.24 million average estimate based on five analysts.
• Revenues- Other: $0.22 million compared to the $2.13 million average estimate based on two analysts.

View all Key Company Metrics for Legend Biotech here>>>

Shares of Legend Biotech have returned -4.8% over the past month versus the Zacks S&P 500 composite's -7.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Legend Biotech Corporation Sponsored ADR (LEGN) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research